Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Joe Stephenson who wrote (265)	2/20/1998 6:25:00 PM
From: Barron Von Hymen	Read Replies (1) \| Respond to of 1321

I think that it may have something to do with strength of their collaboration, viz Pharmacia Upjohn. But revenues from this partnership are declining. But you are right QLT has half the market cap and appears at first glance to be further on track. Also their "cash burn rate" for R&D is much lower, roughly half, but Miravant still has twice as much cash. I'm still amazed at the lack of market response to their news of FDA approval a couple of months ago. Perhaps the news must have been so built up into price near $30. I entered the stock at $18 after they released the news, using an example of Warren Buffett - buy stocks with potential for growth but only at attractive prices.